How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,545 results for

Ulcerative Colitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Ulcerative colitis: management

Ulcerative colitis: management Ulcer Ulcerativ ative colitis: management e colitis: management NICE guideline Published: 3 May 2019 www.nice.org.uk/guidance/ng130 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ulcerative colitis: management (NG130) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 28Contents Contents Overview 4 Who is it for? 4 Recommendations 5 1.1 Patient information and support 5 1.2

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

2. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. (PubMed)

Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Pouchitis occurs in approximately 50% of patients following ileal pouch-anal anastomosis (IPAA) for chronic ulcerative colitis (UC).The primary objective was to determine the efficacy and safety of medical therapies for prevention or treatment of acute or chronic pouchitis.We searched MEDLINE, Embase and CENTRAL from inception to 25 July 2018. We also searched references, trials registers

2019 Cochrane

3. Ulcerative colitis

Ulcerative colitis Evidence Maps - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3

2018 Trip Evidence Maps

4. Biologics versus Immunomodulators for the Treatment of Ulcerative Colitis: A Review of Comparative Clinical Effectiveness and Cost-Effectiveness

Biologics versus Immunomodulators for the Treatment of Ulcerative Colitis: A Review of Comparative Clinical Effectiveness and Cost-Effectiveness Biologics versus Immunomodulators for the Treatment of Ulcerative Colitis: A Review of Comparative Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Biologics versus Immunomodulators for the Treatment of Ulcerative Colitis: A Review of Comparative Clinical Effectiveness and Cost-Effectiveness Biologics versus (...) Immunomodulators for the Treatment of Ulcerative Colitis: A Review of Comparative Clinical Effectiveness and Cost-Effectiveness Last updated: April 17, 2019 Project Number: RD0052-000 Product Line: Research Type: Drug Report Type: Peer-reviewed summary with critical appraisal Result type: Report Question What is the comparative clinical effectiveness of biologics (with or without concomitant immunomodulators) compared with immunomodulators for ulcerative colitis? What is the cost-effectiveness of biologics

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

5. Sequencing of Pharmacological Management of Crohn’s Disease and Ulcerative Colitis: A Review of Guidelines

Sequencing of Pharmacological Management of Crohn’s Disease and Ulcerative Colitis: A Review of Guidelines Sequencing of Pharmacological Management of Crohn’s Disease and Ulcerative Colitis: A Review of Guidelines | CADTH.ca Find the information you need Sequencing of Pharmacological Management of Crohn’s Disease and Ulcerative Colitis: A Review of Guidelines Sequencing of Pharmacological Management of Crohn’s Disease and Ulcerative Colitis: A Review of Guidelines Last updated: January 31, 2019 (...) Project Number: RC1065-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What are the evidence-based guidelines associated with the early use of biologics in the sequencing of pharmacological treatments for patients with moderate to severe Crohn’s disease or ulcerative colitis? Key Message The evidence-based guidelines from Canadian Association of Gastroenterology recommended that for patients with perianal fistulizing Crohn’s disease, anti

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

6. Adalimumab (Idacio) - Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Psoriasis, Arthritis, Psoriatic, Spondylitis, Ankylosing, Uveitis, Hidradenitis Suppurativa, Colitis, Ulcerative, Crohn Disease

Adalimumab (Idacio) - Arthritis, Rheumatoid, Arthritis, Juvenile Rheumatoid, Psoriasis, Arthritis, Psoriatic, Spondylitis, Ankylosing, Uveitis, Hidradenitis Suppurativa, Colitis, Ulcerative, Crohn Disease EMA/85985/2019 EMEA/H/C/004475 Idacio (adalimumab) An overview of Idacio and why it is authorised in the EU What is Idacio and what is it used for? Idacio is a medicine that acts on the immune system (the body’s natural defences) and is used to treat the following conditions: • plaque (...) arthritis (both rare diseases causing inflammation in the joints); • Crohn’s disease (a disease causing inflammation of the gut); • ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut); • hidradenitis suppurativa (also known as acne inversa, a long-term skin disease that causes lumps, abscesses (collections of pus) and scarring on the skin); • non-infectious uveitis (inflammation of the layer beneath the white of the eyeball). Idacio is mostly used in adults when

2019 European Medicines Agency - EPARs

7. Tofacitinib for moderately to severely active ulcerative colitis

Tofacitinib for moderately to severely active ulcerative colitis T T ofacitinib for moder ofacitinib for moderately to se ately to sev verely erely activ active ulcer e ulcerativ ative colitis e colitis T echnology appraisal guidance Published: 28 November 2018 nice.org.uk/guidance/ta547 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. T ofacitinib for moderately to severely active ulcerative colitis (TA547) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 17Contents Contents 1 Recommendations 4 2 Information about

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

8. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. (PubMed)

Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Endoscopic assessment of mucosal disease activity is routinely used to determine eligibility and response to therapy in clinical trials of ulcerative colitis. The operating properties of the existing endoscopic scoring indices are unclear.A systematic review was undertaken to evaluate the development and operating characteristics of endoscopic scoring indices for the evaluation of ulcerative colitis.We searched (...) MEDLINE, Embase and CENTRAL from inception to 5 July 2016. We also searched references and conference proceedings (Digestive Disease Week, United European Gastroenterology Week, European Crohn's and Colitis Organization).Any study design (e.g. randomized controlled trials, cohort studies, case series) that evaluated endoscopic indices for evaluation of ulcerative colitis disease activity were considered for inclusion. Eligible participants were adult patients (> 16 years), diagnosed with ulcerative

2018 Cochrane

10. Ulcerative colitis

Ulcerative colitis Ulcerative colitis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Ulcerative colitis Last reviewed: February 2019 Last updated: September 2018 Summary Ulcerative colitis is a type of inflammatory bowel disease characterised by diffuse inflammation of the colonic mucosa and a relapsing, remitting course. Patients commonly experience bloody diarrhoea, chronic diarrhoea (or both), lower abdominal (...) adenocarcinoma is a complication in 3% to 5% of patients. Definition Ulcerative colitis (UC) is a type of inflammatory bowel disease that characteristically involves the rectum and extends proximally to affect a variable length of the colon. It is recognised as a multifactorial polygenic disease, as the exact aetiology is still unknown. Included in the aetiological theories are environmental factors, immune dysfunction, and a likely genetic predisposition. Podolsky DK. Inflammatory bowel disease. N Engl J

2018 BMJ Best Practice

11. Ulcerative colitis

Ulcerative colitis Ulcerative colitis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Ulcerative colitis Last reviewed: February 2019 Last updated: September 2018 Summary Ulcerative colitis is a type of inflammatory bowel disease characterised by diffuse inflammation of the colonic mucosa and a relapsing, remitting course. Patients commonly experience bloody diarrhoea, chronic diarrhoea (or both), lower abdominal (...) adenocarcinoma is a complication in 3% to 5% of patients. Definition Ulcerative colitis (UC) is a type of inflammatory bowel disease that characteristically involves the rectum and extends proximally to affect a variable length of the colon. It is recognised as a multifactorial polygenic disease, as the exact aetiology is still unknown. Included in the aetiological theories are environmental factors, immune dysfunction, and a likely genetic predisposition. Podolsky DK. Inflammatory bowel disease. N Engl J

2018 BMJ Best Practice

12. Cannabis for the treatment of ulcerative colitis. (PubMed)

Cannabis for the treatment of ulcerative colitis. Cannabis and cannabinoids are often promoted as treatment for many illnesses and are widely used among patients with ulcerative colitis (UC). Few studies have evaluated the use of these agents in UC. Further, cannabis has potential for adverse events and the long-term consequences of cannabis and cannabinoid use in UC are unknown.To assess the efficacy and safety of cannabis and cannabinoids for the treatment of patients with UC.We searched

2018 Cochrane

13. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis

AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis - Gastroenterology Email/Username: Password: Remember me Search AGA Journals Search Terms Search within Search Access provided by Volume 156, Issue 3, Pages 748–764 AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis x Cynthia W. Ko Affiliations Division of Gastroenterology (...) Outline Abbreviations used in this paper: ( ), ( ), ( ), ( ), ( ), ( ), ( ), ( ) This document presents the official recommendations of the American Gastroenterological Association (AGA) on the management of mild-to-moderate ulcerative colitis (UC). The guideline was developed by the AGA Institute’s Clinical Guidelines Committee and approved by the AGA Institute Governing Board. It is accompanied by a technical review x 1 Singh, S., Feuerstein, J.D., Binion, D.G. et al. American Gastroenterological

2019 American Gastroenterological Association Institute

14. Vedolizumab for ulcerative colitis and Crohn's disease

Vedolizumab for ulcerative colitis and Crohn's disease '); } else { document.write(' '); } ACE | Vedolizumab for ulcerative colitis and Crohn’s disease Search > > Vedolizumab for treating ulcerative colitis and Crohn’s disease - Vedolizumab for treating ulcerative colitis and Crohn’s disease Published on 2 January 2019 Guidance Recommendation The Ministry of Health’s Drug Advisory Committee has not recommended listing vedolizumab on the Medication Assistance Fund (MAF) for treating ulcerative (...) colitis and Crohn’s disease because of unacceptable cost-effectiveness compared with biosimilar infliximab at the price proposed by the manufacturer. Factors considered to inform the recommendations for subsidy Technology evaluation Point Item 1.1 The MOH Drug Advisory Committee (“the Committee”) considered the evidence presented for vedolizumab for ulcerative colitis and Crohn's disease. The Agency for Care Effectiveness conducted the evaluation in consultation with clinical experts from the public

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

15. Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC)

Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) October 2019 EUnetHTA Joint Action 3 WP4 1 EUnetHTA Joint Action 3 WP4 Version 1.0, 22/10/2019 Relative effectiveness assessment of pharmaceutical technologies USTEKINUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) WHO HAVE HAD AN INADEQUATE RESPONSE WITH, LOST RESPONSE TO OR WERE INTOLERANT TO EITHER CONVENTIONAL THERAPY OR A BIOLOGIC (...) OR HAVE MEDICAL CONTRAINDICATIONS TO SUCH THERAPIES Project ID: PTJA07 PTJA07 - Ustekinumab for active ulcerative colitis October 2019 EUnetHTA Joint Action 3 WP4 1 DOCUMENT HISTORY AND CONTRIBUTORS Version Date Description V0.1 04/09/19 First draft V0.2 04/10/19 Input from dedicated reviewers has been processed. V0.3 17/10/19 Input from manufacturer and medical editor has been processed. V1.0 22/10/19 Final version Disclaimer The assessment represents a consolidated view of the EUnetHTA assessment

2019 EUnetHTA

16. Early Biologic Treatment versus Conventional Step-Up Treatment for the Management of Ulcerative Colitis: Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Early Biologic Treatment versus Conventional Step-Up Treatment for the Management of Ulcerative Colitis: Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines Early Biologic Treatment versus Conventional Step-Up Treatment for the Management of Ulcerative Colitis: Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Early Biologic Treatment versus Conventional Step-Up Treatment for the Management of Ulcerative Colitis (...) : Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines Early Biologic Treatment versus Conventional Step-Up Treatment for the Management of Ulcerative Colitis: Comparative Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: November 20, 2018 Project Number: RA0987-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical effectiveness and safety of early biologic treatment compared with conventional step-up

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

17. Xeljanz - tofacitinib - Ulcerative colitis

Xeljanz - tofacitinib - Ulcerative colitis tofacitinib | CADTH.ca Find the information you need tofacitinib tofacitinib Last Updated: April 23, 2019 Result type: Reports Project Number: SR0572-000 Product Line: Generic Name: tofacitinib Brand Name: Xeljanz Manufacturer: Pfizer Canada Inc. Indications: Ulcerative colitis Manufacturer Requested Reimbursement Criteria 1 : Indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) with an inadequate

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

18. Adalimumab (Hyrimoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Papulosquamous Skin Diseases, Hidradenitis Suppurativa, Ankylosing Spondylitis, Uveitis

Adalimumab (Hyrimoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Papulosquamous Skin Diseases, Hidradenitis Suppurativa, Ankylosing Spondylitis, Uveitis 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how (...) have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and / or an immunomodulator, or who are intolerant to or have contraindications for such therapies. Ulcerative colitis Hyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant

2018 European Medicines Agency - EPARs

19. Infliximab (Zessly) - Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Psoriasis, Ankylosing Spondylitis

Infliximab (Zessly) - Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Psoriasis, Ankylosing Spondylitis 22 March 2018 EMA/223369/2018 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Zessly International non-proprietary name: infliximab Procedure No. EMEA/H/C/004647/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU (...) therapy; or who are intolerant to or have contraindications for such therapies. Infliximab has been studied only in combination with conventional immunosuppressive therapy. Ulcerative colitis Zessly is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications

2018 European Medicines Agency - EPARs

20. Histologic scoring indices for evaluation of disease activity in ulcerative colitis. (PubMed)

Histologic scoring indices for evaluation of disease activity in ulcerative colitis. Disease activity can be determined using clinical, endoscopic or histologic criteria in patients with ulcerative colitis (UC). Persistent disease activity is associated with poor outcomes. Histologic disease activity has been shown to be associated with relapse, colectomy and colorectal cancer. The ability to objectively evaluate microscopic disease activity using histology is important for both clinical (...) practice and clinical trials. However, the operating properties of the currently available histologic indices remain unclear.A systematic review was undertaken to identify and evaluate the development and operating characteristics of histologic disease activity indices used to assess disease activity in people with ulcerative colitis.We searched MEDLINE, EMBASE, PubMed, CENTRAL and the Cochrane IBD Review Group Specialized Trials Register from inception to 2 December 2016 for applicable studies

2017 Cochrane

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>